A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
The American Coalition for Clean Coal Electricity today released a new report “Energy Cost Impacts on Families” that details the plight of American households who are significantly harmed by rising energy costs.
The study finds that on average nearly half of America’s households are bringing home $1,900 a month, less than $23,000 annually, and spending 17 percent of those hard-earned dollars on energy. Low and fixed income families, including minorities and senior citizens, are among the most vulnerable to energy price increases and frequently must make tough choices about what to do to meet energy costs.
“No one should go without food or medication to keep the lights on but that’s exactly what is taking place in millions of households across America,” said Mike Duncan, president and CEO of ACCCE. “Regulations like EPA’s calamitous Clean Power Plan will only exacerbate the economic struggles families face, making it all that much harder to keep a roof over their heads and food on the table. This administration should put Americans ahead of its politically charged agenda and immediately take action to ensure vulnerable families are not harmed further by these reckless regulations.”
To view the Multimedia News Release, go http://www.multivu.com/players/English/7552751-accce-family-energy-impact-report/
http://acne.gd/what-is-the-best-way-to-get-rid-of-my-acne/ In case your for the greatest method to remove pimple quickly then this short article can help you a lot. First off I am likely to show you whats going on with your encounter and why individuals pimples just keep popping up. After I let you know my secret in this article you can take a look at my blog below for a full detailed guide on how to remove your acne. Very first things very first though, I am likely to provide you with a single trick that assisted my pimple much more then any cream or medication.
Do You Rest Inside a Short Sleeved Tank top?
Nicely should you do then you definitely may be hurting your probabilities of obtaining eliminate of the pimples greatly. Yes that
West Pharmaceutical Services, Inc. (NYSE: WST) and HealthPrize Technologies, LLC, today announced the completion of the first two phases of their four-phase strategic collaboration. The companies are working to integrate HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient-engagement platform with West’s injectable drug delivery systems to provide an end-to-end connected health solution for pharmaceutical companies and the patients they serve. The combined offering will provide voluntary, electronically connected drug delivery systems that track when patients take their medication. The HealthPrize system engages and educates patients to increase adherence and medical literacy, rewarding interaction and compliance with prescribed treatment plans, and contributing to better health outcomes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7625851-west-pharma-healthprize-tech-collaboration/
Drugs are everywhere. The use of prescription painkillers has increased dramatically in recent years, and prescription drug abuse is now the nation’s fastest-growing drug problem. According to the U.S. Department of Health and Human Services, more than 5 million Americans misuse painkillers each month. Opioid painkillers—a class of very powerful and potentially addicting pain relievers—are the most common source of drug overdose deaths, resulting in more unintentional deaths than cocaine and heroin combined.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prescriptiondrugabuse/50825/
Eight out of 10 people will be affected by back pain at some point during their lives, making it the No. 1 cause of disability worldwide and resulting in as much as $200 billion in lost wages and productivity. Many sufferers struggle for years to find relief, but treatment options often only provide short-term relief or, in the case of pain medication, carry serious side effects, including drowsiness, liver damage and potential for addiction. Now, thanks to Hocoma, a leader in the development of robotic and sensor-based medical devices for functional movement therapy, consumers have a new way to improve and sustain low back health in the comfort of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7370551-hocoma-innovative-medical-device-therapeutic-gaming-technology-valedo-low-back-health/
The U.S. Food and Drug Administration (FDA) Office of Women’s Health today released a new public service announcement (PSA) titled, “Use Medicines Wisely,” to help raise awareness about safe medication use.
Millions of people benefit from FDA approved medications and are living longer productive lives. However, when medications are used incorrectly, they can cause serious injuries, even death. Many of these injuries can be prevented.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/fda/50878/
TruTag Technologies, Inc., Honolulu-based innovator of an edible security platform to address the trillion dollar global counterfeit problem and the issue of food and medicine safety, has been named a 2014 Technology Pioneer by the World Economic Forum.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63075-trutag-technologies-2014-technology-pioneer-by-world-economic-forum
Many children and teens suffering from tachycardia, or rapid heart rate, have relied on medication to regulate their heart rhythms and control symptoms such as fatigue, dizziness and fainting spells. However, doctors at the Akron Children’s Hospital Arrhythmia Center have made great strides in curing tachycardia with minimally invasive procedures.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51056-akron-childrens-hospital-arrhythmia-tachycardia-cryoablation
If you take on medication to cure your hiatus, it's not going to happen.
A more serious condition of hiatus will require a lot of attention from you.
But even so, you can get relief with natural remedies.
This video will give you some information on how you can get rid of this painful and annoying condition
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
Se pone en marcha el primer estudio integral a largo plazo que compara diferentes medicaciones para el tratamiento de la diabetes tipo 2 a escala nacional. El estudio GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness - Estrategias para la reducción de la glucemia en la diabetes: una comparativa de la eficacia) comparará los efectos beneficiosos y riesgos a largo plazo de cuatro fármacos ampliamente utilizados en el tratamiento de la diabetes, en combinación con metformina, la medicación de primera línea más frecuente para tratar la diabetes tipo 2. El estudio GRADE está buscando voluntarios latinos.
Para ver el Multimedia News Release, vaya a http://www.multivu.com/mnr/65066-nih-grade-study-on-type-2-diabetes-medication-seeks-latino-volunteers
